Navigation Links
Pegasys in Medical News

Human Genome Sciences Announces Second-Quarter 2009 Financial Results and Key Developments

...IEVE 2/3, showed that ZALBIN met its primary endpoint of non-inferiority to pegasys (peginterferon alfa-2a). With half the injections, ZALBIN achieved a rate of sustained virologic response comparable to pegasys in these studies, with rates of serious and/or severe adverse events that a...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...-37 Table 12: Major Side Effects Associated with HCV Treatment with pegasys + Copegus Combination Therapy and Pegasys Monotherapy (includes corresponding Graph/Chart) II-38 Table 13: Comparison Between PEG-Intron and pegasys in Monotherapy and Combination Therapy in HCV Treatment (includes c...

Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients

... clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase...

Pharmasset to Present at Deutsche Bank Healthcare Conference

... clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase...

Roche Women Honored as 2009 TWIN Awardees

...ack-to-basics" Success campaign in the last 18 months that differentiated pegasys through its efficacy, safety and ease of use - a message that embodied what... Klein, vice president, Virology Sales and Marketing. "Under her direction, pegasys has clearly established itself the market leader, and the value of the fran...

In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response

...o peginterferon/ribavirin provide advantages in this attribute over Roche's pegasys (peginterferon-a-2a) plus ribavirin, the sales-leading treatment in the mar...ion Resources' proprietary clinical gold standard for hepatitis C virus was pegasys plus ribavirin because of its advantages in delivery and dosing. Based on a...

PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine

...zed trial, was designed to compare the efficacy of pegasys plus COPEGUS in 269 Latino whites and 300 non-Lati..., between the ages of 18 and 65, were treated with pegasys 180 mcg/wk plus COPEGUS 1,000 or 1,200 mg/day for ...the Latino patients achieved SVR when treated with pegasys plus COPEGUS.(1) In comparison, 49 percent (148/30...

InterMune Reports Results from Triple Combination Study of ITMN-191

...s of various doses and regimens of ITMN-191 for 14 days in combination with pegasys and Copegus compared to treatment with pegasys and Copegus alone. Patient follow-up continues for 30 days following the c...

Pharmasset Reports Financial Results for Quarter Ended March 31, 2008

...l 12-week Phase 2b combination study of R7128 with pegasys plus Copegus." Highlights of the Quarter Ended...500mg) in a 4-week combination study of R7128 with pegasys plus Copegus for the treatment of HCV. -- App... 4 in a 4-week combination study of R7128 with pegasys plus Copegus for the treatment of HCV in the t...

HGS announces results of Phase 2B trial of Albuferon for chronic hepatitis C

...with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. This Phase 2b study demonstrated that, with half as many injections as pegasys (peginterferon alfa 2a), Albuferon was just as effective in achieving sustained virologic response (SVR) an undetectable amount of virus in the blood...
Pegasys in Medical Technology

Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron

WASHINGTON--(BUSINESS WIRE)--May 21, 2007 - Roche today announced results of a small study demonstrating that all patients who discontinued treatment with Peg-Intron(R) (peginterferon alfa-2b) and ribavirin due to adverse events within the first 12 weeks, were able to complete 12 weeks of treatment...

Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences

... clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

...ibavirin is the current standard of care for HCV. pegasys is the leading treatment for HCV, and also is the ... for 14 days as monotherapy and when combined with pegasys and COPEGUS. R7227 was safe and well-tolerated in... R7128 was safe and well-tolerated when given with pegasys and COPEGUS for up to 28 days. About...

Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C

...ions, in two pivotal Phase 3 trials, Albuferon (albinterferon alfa-2b) met the primary efficacy endpoint of sustained virologic response comparable to pegasys (peginterferon alfa-2a) - - Patients receiving 900-mcg Albuferon had comparable rates of serious and/or severe adverse events across the two Pha...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

...virologic response rates (RVR) in combination with pegasys and COPEGUS. Unlike protease inhibitors in develop...bination of R7128 and the current gold standard of pegasys and COPEGUS can provide a more potent - and potent...reatment, with R7128 500mg bid in combination with pegasys and COPEGUS for 12 weeks, followed by 12 weeks of...

InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)

...any patient receiving treatment with ITMN-191 plus pegasys and ribavirin. ITMN-191 plus standard-of-c...gimens of ITMN-191 for 14 days in combination with pegasys and Copegus compared to treatment with pegasys and Copegus alone. Patient follow-up continued fo...

Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients

...tly developing three product candidates. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with pegasys plus COPEGUS through a strategic collaboration with Roche, and is initiating a Phase 2b trial. Racivir, which is being developed for the treatment of ...

InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009

...al kinetic effects of ITMN-191 administered for 14 days in combination with pegasys and Copegus compared to the effects of pegasys and Copegus alone. The protocol includes both twice-daily and three-times-...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

...y (MIST) randomly assigned 431 patients to receive pegasys or PegIntronTM, both in combination with ribavirin. In the pegasys group, the daily ribavirin dose for genotype 1 and...e significantly more patients to achieve a SVR." pegasys has demonstrated efficacy in a broad range of pati...

Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C

...wing 4 weeks of treatment with R7128 1000mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with pegasys plus Copegus - PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announces the prelimi...
Pegasys in Biological News

Biolex presents Locteron US Phase 2a hepatitis C data at EASL

...o Locteron's controlled-release mechanism, the currently approved products, pegasys and PEG-Intron, and the investigational product Albuferon, are immediate-re...on is configured to allow dosing once every two weeks, more convenient than pegasys and PEG-Intron, each of which require dosing every week. More importantly, ...
Pegasys in Biological Technology

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

...opean Association for the Study of the Liver (EASL) in late April, results were reported from a 14-day, Phase 1b study of ITMN-191 in combination with pegasys and ribavirin. After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six ...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

... clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase...

Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments

...eron (albinterferon alfa-2b) met its primary endpoint of non-inferiority to pegasys (peginterferon alfa-2a) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon...s, in two pivotal Phase 3 trials, Albuferon achieved efficacy comparable to pegasys with a positive safety profile. The submission of global marketing applica...

Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C

... - Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to pegasys (peginterferon alfa-2a) in the ACHIEVE 2/3 trial in patients with genotypes 2 and 3 chronic hepatitis C - - Patients receiving 900-mcg Albuf...

Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders

...ith R7128 1500mg BID with Pegasys(R) plus Copegus(R) - - Safety and tolerability comparable to placebo administered with pegasys plus Copegus - PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announces the prelim...

InterMune Reports Second Quarter 2008 Financial Results and Business Highlights

...iviral compounds. -- InterMune expects to announce top-line results from the currently running 14-day study of ITMN-191 in combination with pegasys and ribavirin in the fourth quarter of 2008. Conference Call and Webcast Details InterMune will host a conference call today at 4:30 p.m. E...

Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study

...rts 3 and 4 will both be dosed in combination with pegasys (peginterferon alfa-2a) plus Copegus (ribavirin). ...mg and 1500mg cohorts of R7128 in combination with pegasys plus Copegus suggests that the 1000mg dose could d...nts receiving R7128 1500mg twice- daily (BID) with pegasys plus Copegus for 4 weeks achieved undetectable HCV...

Pharmasset Receives $10 Million of Working Capital

... will not provide meaningful data, the risk that we will fail to release final safety and efficacy data from a Phase 1 combination study of R7128 with pegasys plus Copegus or that such final data will not corroborate our preliminary results, the risk that the on-going or anticipated clinical trials for any o...

Pharmasset Appoints Herbert J. Conrad as a Director

...outh Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with pegasys plus Copegus through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approv...

Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year

... for hepatitis C, and that fewer patients treated with both PEGINTRON regimens relapsed after the end of treatment compared to those receiving pegasys and Copegus. (Announced Jan. 14, 2008) -- Announced that Schering-Plough Chairman/CEO Fred Hassan intends to make an open market purchase of $2 ...
Other Tags
(Date:11/24/2014)... 24, 2014 Volpara Solutions announced ... at the 100th Annual Meeting of the Radiology ... 2014 (RSNA Booth 1752 – South Hall). Volpara ... and the rest of its innovative suite of ... which enable personalized measurements of volumetric density, patient-specific ...
(Date:11/24/2014)... SweetDressy.com, a well-known dress supplier and leader in the ... Dresses. All these fresh items are offered at affordable ... special offer is valid until Dec. 20, 2014. Click ... working well in the fashion industry for years. They ... dresses may be the best products for many ladies ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... Vancouver, BC (PRWEB) November 23, 2014 Pro ... recently announced that it will now be providing an 8 ... number of hot water tank installations went up due to ... Care to assure its customers of the premium service that ... be offering 8 year warranty on John Wood and Bradford ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
(Date:11/10/2014)... pods began appearing on U.S. store shelves in early ... ever since. The small packets can be tossed into ... a liquid or powder. The convenience, though, has come ... from researchers at Nationwide Children,s Hospital found that from ... of 17,230 children younger than 6 years of age ...
(Date:11/6/2014)... -- A groundbreaking paper from a team of Florida ... of how plants could adapt to and survive environmental ... published in the latest issue of the journal ... (the complex of DNA and proteins) is organized in ... that some genes are turned on and others are ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2Maize analysis yields whole new world of genetic science 2
Other Contents